Feel really sorry for any RAP holders.
Share price pummelled after results from studies suggest many issues with recording audible coughs.
RAP was at one stage valued at $300M+ and 55c per share in October 2016. Now 6c!
Those who may want to keep funds in healthcare may look for other opportunities.
I'm very comfortable with holding MDR. They have revenue and building more through other products/services. Low market cap with the business based on verifiable numbers (patients, pharmacies, big pharma) not an algorithm that has the possibility of solving health issues.
AFR article, page-13
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
